secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001641172-25-009939
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience Q1 2025: Cash $10.3M, R&D down 31%, expects first revenue in Q4 2025
--------------------------------------------------------------------------------

- Cash and equivalents $10.3M at March 31, 2025; working capital deficit of $9.4M.
- R&D expenses fell 31% YoY to $2.3M; G&A expenses decreased to $2.3M from $2.7M.
- Targeting first revenue in Q4 2025 via Sildenafil Cream as 503B compounded drug; DARE-HRT1 in 2026.
- Ovaprene Phase 3 contraceptive efficacy study ongoing; interim DSMB review scheduled for July 2025.
- Strategy shift: dual path of 503B compounding and FDA approval; aiming for four on-market products by 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000164117225009939/0001641172-25-009939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000164117225009939/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer